![[HTML version]](/e/graphics/htmlborder.gif)
![[PDF version]](/e/graphics/pdfborder.gif)
![[CIF]](/e/graphics/cifborder.gif)
![[3d view]](/e/graphics/3dviewborder.gif)
![[Structure Factors]](/e/graphics/structurefactorsborder.gif)
![[CIF check Report]](/e/graphics/checkcifborder.gif)
![[Buy article online]](/logos/buy.gif)
![[Contents scheme]](cm6017contents.gif)
Acta Cryst. (2002). E58, o1169-o1171 [ doi:10.1107/S1600536802017683 ]
Abstract: The title compound, (+)-(3S,4R)-cis-4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-1-ium-4-yl)benzamidehydrogen (2R,3R)-dihydroxybutanedioate monohydrate, C14H21ClN3O3+·C4H5O6-·H2O, is the (+)-tartrate salt of (+)-norcisapride. It has been found that (+)-norcisapride has both 5-HT3 antagonistic and 5-HT4 agonistic properties and is further substantially devoid of central nervous system effects. An intramolecular N-H
O hydrogen bond forces the amido group to be roughly coplanar with the substituted benzene ring. A three-dimensional network of hydrogen bonds is formed in the crystal. The absolute configuration of (+)-norcisapride is 3S,4R.
Online 30 September 2002
Copyright © International Union of Crystallography
IUCr Webmaster